Albumin is a type of protein present in blood plasma, serum, muscle, egg whites, milk, and other animal substances, as well as in various plant tissues and fluids. It is a simple protein that is heat-coagulable and water-soluble, playing a vital role in maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body.
The primary types of albumin are human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin, found in blood plasma, helps maintain osmotic pressure and transports various substances such as hormones and fatty acids. Its applications include therapeutics, drug formulation, vaccines, and media components, distributed through channels such as business-to-customer (B2C) and business-to-business (B2B). The end users of albumin include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.
The albumin research report is one of a series of new reports that provides albumin market statistics, including the albumin industry's global market size, regional shares, competitors with an albumin market share, detailed albumin market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. This albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The albumin market size has grown strongly in recent years. It will grow from $6.03 billion in 2023 to $6.57 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be credited to advancements in biotechnology, a higher demand for plasma-derived therapies, expanding pharmaceutical applications, a high prevalence of liver diseases, regulatory approvals for albumin-based products, and the globalization of healthcare, which has led to wider market access.
The albumin market size is expected to see strong growth in the next few years. It will grow to $9.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth expected in the forecast period can be attributed to the increasing prevalence of liver diseases, expanding applications in regenerative medicine, a rising geriatric population, evolving diagnostic techniques, a shift in healthcare infrastructure towards outpatient care, and growing awareness about the importance of maintaining optimal protein levels. Major trends during the forecast period include expanding therapeutic applications, increasing adoption in drug delivery systems, higher demand in cell culture media, growth in personalized medicine, advancements in recombinant technology, heightened awareness of hypoalbuminemia treatment, and significant investment in research and development for innovative albumin-based products.
The increasing prevalence of diabetes is poised to drive growth in the albumin market moving forward. Diabetes, a metabolic disorder characterized by prolonged high blood sugar levels, is on the rise due to factors such as poor nutrition, sedentary lifestyles, hormonal conditions, and obesity. Albumin plays a critical role in diabetes management as a significant biomarker, guiding insulin therapy, monitoring glycemic control, aiding diagnosis, and predicting complications such as diabetic ketoacidosis (DKA). Maintaining normal albumin levels is crucial for effectively managing diabetes. According to the National Library of Medicine, global diabetes prevalence was estimated at 10.5% in 2021, affecting approximately 536.6 million individuals aged 20-79 years. Projections suggest this figure could reach 12.2% by 2045, impacting about 783.2 million people. Therefore, the rising incidence of diabetes is expected to drive growth in the albumin market.
Leading companies in the albumin market are focusing on innovation, developing products such as animal- and human-origin-free recombinant albumin to meet increasing demand with advanced features. This type of albumin is produced using non-mammalian expression systems such as yeast and does not contain any animal- or human-derived components. For example, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), collaborated with Heartseed Inc., a Japan-based clinical-stage biotech company, to introduce Recombin as a critical excipient for Heartseed's investigational cell therapy, HS-001, during its first-in-human clinical trial. This partnership represents a significant milestone in advancing HS-001, promising innovative treatment approaches for various diseases. The use of recombinant technology ensures optimal performance and stability of the cell therapy, enhancing its potential for therapeutic success.
In September 2022, Sartorius AG, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Albumedix, strengthening its position in the expanding sector of advanced therapies and vaccines. This acquisition aligns Albumedix's innovative recombinant albumin technology with Sartorius' portfolio of cell culture media and process solutions, bolstering the company's offerings in the dynamic market landscape of advanced therapies. Albumedix Ltd. is a UK-based provider of high-quality recombinant human albumin solutions.
Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.
North America was the largest region in the albumin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The primary types of albumin are human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin, found in blood plasma, helps maintain osmotic pressure and transports various substances such as hormones and fatty acids. Its applications include therapeutics, drug formulation, vaccines, and media components, distributed through channels such as business-to-customer (B2C) and business-to-business (B2B). The end users of albumin include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.
The albumin research report is one of a series of new reports that provides albumin market statistics, including the albumin industry's global market size, regional shares, competitors with an albumin market share, detailed albumin market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. This albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The albumin market size has grown strongly in recent years. It will grow from $6.03 billion in 2023 to $6.57 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be credited to advancements in biotechnology, a higher demand for plasma-derived therapies, expanding pharmaceutical applications, a high prevalence of liver diseases, regulatory approvals for albumin-based products, and the globalization of healthcare, which has led to wider market access.
The albumin market size is expected to see strong growth in the next few years. It will grow to $9.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth expected in the forecast period can be attributed to the increasing prevalence of liver diseases, expanding applications in regenerative medicine, a rising geriatric population, evolving diagnostic techniques, a shift in healthcare infrastructure towards outpatient care, and growing awareness about the importance of maintaining optimal protein levels. Major trends during the forecast period include expanding therapeutic applications, increasing adoption in drug delivery systems, higher demand in cell culture media, growth in personalized medicine, advancements in recombinant technology, heightened awareness of hypoalbuminemia treatment, and significant investment in research and development for innovative albumin-based products.
The increasing prevalence of diabetes is poised to drive growth in the albumin market moving forward. Diabetes, a metabolic disorder characterized by prolonged high blood sugar levels, is on the rise due to factors such as poor nutrition, sedentary lifestyles, hormonal conditions, and obesity. Albumin plays a critical role in diabetes management as a significant biomarker, guiding insulin therapy, monitoring glycemic control, aiding diagnosis, and predicting complications such as diabetic ketoacidosis (DKA). Maintaining normal albumin levels is crucial for effectively managing diabetes. According to the National Library of Medicine, global diabetes prevalence was estimated at 10.5% in 2021, affecting approximately 536.6 million individuals aged 20-79 years. Projections suggest this figure could reach 12.2% by 2045, impacting about 783.2 million people. Therefore, the rising incidence of diabetes is expected to drive growth in the albumin market.
Leading companies in the albumin market are focusing on innovation, developing products such as animal- and human-origin-free recombinant albumin to meet increasing demand with advanced features. This type of albumin is produced using non-mammalian expression systems such as yeast and does not contain any animal- or human-derived components. For example, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), collaborated with Heartseed Inc., a Japan-based clinical-stage biotech company, to introduce Recombin as a critical excipient for Heartseed's investigational cell therapy, HS-001, during its first-in-human clinical trial. This partnership represents a significant milestone in advancing HS-001, promising innovative treatment approaches for various diseases. The use of recombinant technology ensures optimal performance and stability of the cell therapy, enhancing its potential for therapeutic success.
In September 2022, Sartorius AG, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Albumedix, strengthening its position in the expanding sector of advanced therapies and vaccines. This acquisition aligns Albumedix's innovative recombinant albumin technology with Sartorius' portfolio of cell culture media and process solutions, bolstering the company's offerings in the dynamic market landscape of advanced therapies. Albumedix Ltd. is a UK-based provider of high-quality recombinant human albumin solutions.
Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.
North America was the largest region in the albumin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Albumin Market Characteristics3. Albumin Market Trends And Strategies32. Global Albumin Market Competitive Benchmarking33. Global Albumin Market Competitive Dashboard34. Key Mergers And Acquisitions In The Albumin Market
4. Albumin Market - Macro Economic Scenario
5. Global Albumin Market Size and Growth
6. Albumin Market Segmentation
7. Albumin Market Regional And Country Analysis
8. Asia-Pacific Albumin Market
9. China Albumin Market
10. India Albumin Market
11. Japan Albumin Market
12. Australia Albumin Market
13. Indonesia Albumin Market
14. South Korea Albumin Market
15. Western Europe Albumin Market
16. UK Albumin Market
17. Germany Albumin Market
18. France Albumin Market
19. Italy Albumin Market
20. Spain Albumin Market
21. Eastern Europe Albumin Market
22. Russia Albumin Market
23. North America Albumin Market
24. USA Albumin Market
25. Canada Albumin Market
26. South America Albumin Market
27. Brazil Albumin Market
28. Middle East Albumin Market
29. Africa Albumin Market
30. Albumin Market Competitive Landscape And Company Profiles
31. Albumin Market Other Major And Innovative Companies
35. Albumin Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Albumin Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on albumin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for albumin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The albumin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Human Serum Albumin; Bovine Serum Albumin; Recombinant Albumin2) By Application: Therapeutics; Drug Formulation And Vaccines; Component Of Media; Other Applications
3) By Sales Channel: Business-To-Consumer (B2C); Business-To-Business (B2B)
4) By End-User: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Research Institutes
Key Companies Mentioned: Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Merck KGaA; Baxter International Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific Inc.
- Takeda Pharmaceutical Company Limited
- Merck KGaA
- Baxter International Inc.
- CSL Limited
- Grifols SA
- Mitsubishi Tanabe Pharma Corporation
- Octapharma AG
- Kedrion S.p.A.
- Biotest AG
- Jiangxi Boya Bio-Pharmaceutical Co. Ltd.
- BPL (Bio Products Laboratory)
- Kamada Ltd.
- Proliant Biologicals
- SeraCare Life Sciences Inc.
- HiMedia Laboratories
- Albumedix Ltd.
- Medxbio Pte Ltd.
- Ventria Bioscience Inc.
- China Biologic Products Holdings Inc.
Methodology
LOADING...